NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
17/05/2024
Voltar para busca
Dado oficial do USPTO
LIVERTY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
39
Atualização mais recente
17/05/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
15/11/2012
Data de registro
08/04/2014
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/05/2024
Última transação
17/05/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
30/07/2013
Primeiro uso no comércio
30/07/2013
Código do desenho
4
Tipo de titular
03
Localização do titular
New Taipei City, TW
Examinador
SPARER, ZACHARY R
Unidade examinadora
M60
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
G. C. (pessoa física)
Representantes
Joe McKinney Muncy Muncy, Geissler, Olds & Lowe, P.C
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Adjuvants for medical purposes; antiallergic medicines; anti-cancer preparations; medicinal herbal extracts for medical purposes; pharmaceutical and medicinal preparations and substances for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of inflammatory disordersocular disordersbone diseasesfor use in dermatologyoncologyhematology and ophthalmology and for gastroenterological disorders or liver ailments; pharmaceutical and medicinal preparations for the treatment of brain diseases or disorders and autoimmune diseases or disorders; dietary and nutritional supplements for medical use; dietary supplements for treating fatigue or liver support; animal feed additive for use as a nutritional supplement for medical purposes; dietary supplements for human consumption or for animals; nutritional additives in the nature of a dietary supplement for medical purposes for use in foods for human consumption or for animals; animal feed supplements; dietary pet supplements in the form of pet treats; fungi preparations for medical or veterinary use for treating disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of inflammatory disordersocular disordersbrain diseases or disordersautoimmune diseases or disordersbone diseasesfor use in dermatologyoncologyhematology and ophthalmology and for gastroenterological disorders or liver ailments; pharmaceutical preparations and substances for veterinary purposes for treating disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of inflammatory disordersocular disordersbrain diseases or disordersautoimmune diseases or disordersbone diseasesfor use in dermatologyoncologyhematology and ophthalmology and for gastroenterological disorders or liver ailments; chemical preparations for medicinal purposes for treating disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of inflammatory disordersocular disordersbrain diseases or disordersautoimmune diseases or disordersbone diseasesfor use in dermatologyoncologyhematology and ophthalmology and for gastroenterological disorders or liver ailments; cardiovascular pharmaceuticals; cardiovascular treatment preparations; pharmaceuticals preparations for the treatment of kidney diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
39 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
17/05/2024
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
17/05/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
17/05/2024
E89R
TEAS SECTION 8 & 9 RECEIVED
02/02/2024
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
08/04/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
23/12/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
23/12/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/12/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/12/2022
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
01/12/2019
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
01/12/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/12/2019
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/11/2019
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/11/2019
E815
TEAS SECTION 8 & 15 RECEIVED
28/10/2019
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
08/04/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
08/04/2014
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/03/2014
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
04/03/2014
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
25/02/2014
SUPC
STATEMENT OF USE PROCESSING COMPLETE
24/02/2014
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
17/02/2014
IUAF
USE AMENDMENT FILED
21/01/2014
EISU
TEAS STATEMENT OF USE RECEIVED
21/01/2014
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
30/07/2013
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/06/2013
PUBO
PUBLISHED FOR OPPOSITION
04/06/2013
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/05/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/05/2013
ALIE
ASSIGNED TO LIE
20/04/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/04/2013
XAEC
EXAMINER'S AMENDMENT ENTERED
14/03/2013
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/03/2013
GNEA
EXAMINERS AMENDMENT E-MAILED
14/03/2013
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/03/2013
DOCK
ASSIGNED TO EXAMINER
12/03/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/11/2012
NWAP
NEW APPLICATION ENTERED
19/11/2012
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LIVERTY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.